Jeffrey Zwicker, MD
Hematologist
My Role at MSKWe post reviews for MSK healthcare providers who have at least 30 patient experience surveys completed. If you do not see reviews for a provider, it may be because they do not yet have enough survey responses, or the provider may not be part of the group of healthcare providers included in the survey.
Only outpatient providers are included in the survey. Healthcare providers who only work in the hospital or in urgent care are not included in the survey. Pathologists or researchers who do not provide direct care to patients do not have reviews.
Areas of Expertise
My Specialties
- Deep Vein Thrombosis and Pulmonary Embolism
- Anticoagulation
- Blood Count Disorders (i.e., Anemia, Low or Elevated Platelet Count)
Request an Appointment
About Me
- Chief, Hematology Service
As Chief of the Hematology Service at Memorial Sloan Kettering Cancer Center (MSK), I lead a team of hematologists that sees approximately 4,040 patients with benign blood disorders each year.
At MSK, my fellow hematologists and I collaborate to deliver personalized cancer care that considers each patient’s needs and preferences. When I meet with patients, I don’t just treat them as if they were my own family members — I try to put myself in their shoes.
Often, patients are concerned about the blood-related complications that can occur with cancer treatment. Some of the most common questions that patients ask me relate to the likelihood of experiencing blood-related complications on a medication, other possible side effects, and how long they need to be on a specific therapy. I take the time to clearly explain what patients can expect and address the concerns related to their condition. No matter the diagnosis, there is world-class expertise at MSK.
Read more
In patients with cancer, blood-related disorders, such as blood clots, low blood counts including anemia, and bleeding disorders, which may require special attention, regardless of whether the disorder is pre-existing, or a side effect of cancer treatment. Patients who already had a blood disorder before they were diagnosed with cancer might tailored therapies.
Sometimes, patients receiving cancer therapy will experience blood-related side effects. These can include blood clots that form in a deep vein (deep vein thrombosis [DVT]) or decreases in the number of platelets in the blood (thrombocytopenia). Cancer-associated thrombosis is a condition that can develop when someone is undergoing treatment for cancer. Beyond caring for existing blood-related disorders, the Hematology Service also provides prompt medical attention to address any blood-related side effects, including thrombosis.
In addition to caring for patients with benign blood disorders, I study cancer-associated thrombosis to better understand its risk factors and develop novel treatment approaches. To date, I have led several National Institutes of Health-funded studies in cancer-associated thrombosis. I currently serve as the Chair of the International Society on Thrombosis and Haemostasis. Inc.’s (ISTH) subcommittee on hemostasis and thrombosis. I also previously acted as the Vice-Chair and Chair of the American Society of Hematology’s subcommittee on thrombosis and vascular biology. Through research and leadership in national and international professional organizations dedicated to thrombosis, I hope to improve the prevention and treatment of cancer-associated thrombosis.
A hematologist (HEE-muh-TAH-loh-jist) is a doctor with special training in blood disorders.
My Specialties
- Deep Vein Thrombosis and Pulmonary Embolism
- Anticoagulation
- Blood Count Disorders (i.e., Anemia, Low or Elevated Platelet Count)
Education
- MD, Penn State College of Medicine
- MMS, Harvard Medical School
Residencies
- Intern and Resident, Beth Israel Deaconess Medical Center, Harvard Medical School
Awards and Honors
- Gordon J. Strewler Mentorship of Resident Research Award, Department of Medicine, Beth Israel Deaconess Medical Center (2021)
- Program for Emerging Leaders, Harvard Medical School (2015)
- Merck Award for Outstanding Academic Performance, Penn State College of Medicine (1998)
Fellowships
- Hematology/Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School
Board Certifications
- Hematology
Insurance Information
Understanding your insurance options is an important part of managing your cancer care. We have relationships with many common healthcare providers and plans.
In Network Coverage Type
PPO
In Network Coverage Type
HMO, PPO
In Network Coverage Type
HMO, EPO PPO, POS
In Network Coverage Type
PPO
In Network Coverage Type
EPO
In Network Coverage Type
EPO
In Network Coverage Type
Federal Government
In Network Coverage Type
PPO, POS, EPO, HMO
In Network Coverage Type
State Government
Don't see your carrier or plan? We can help you understand your coverage.
If you don't have health insurance or are worried that your care may not be fully covered, our financial assistance programs may be able to help.
If you have questions about insurance, call us at 646-497-9176.
Make an Appointment
New Patients
Current Patients
Contact and Location
Dr. Zwicker sees patients at one location.
Looking to see a doctor at a different location? See all MSK locations.
Colleagues
Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.
Clinical Trials
Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.
You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.
Search clinical trialsResearch and Publications
View a list of Dr. Zwicker’s publications.
Wang TF, Sanfilippo KM, Douketis J, Falanga A, Karageorgiou J, Maraveyas A, Ortel TL, Soff G, Vedantham S, Zwicker JI. Peri-procedure management of antithrombotic agents and thrombocytopenia for common procedures in oncology: Guidance from the SSC of the ISTH. J Thromb Haemost. 2022 Sep 26. doi: 10.1111/jth.15896. Epub ahead of print. PMID: 36217296.
Khan AM, Chiasakul T, Redd R, Patell R, McCarthy EP, Neuberg D, Zwicker JI. Survival outcomes with warfarin compared with direct oral anticoagulants in cancer-associated venous thromboembolism in the United States: A population-based cohort study. PLoS Med. 2022 May 25;19(5):e1004012. doi: 10.1371/journal.pmed.1004012. PMID: 35613184; PMCID: PMC9182592.
Sharda AV, Bogue T, Barr A, Mendez LM, Flaumenhaft R, Zwicker JI. Circulating Protein Disulfide Isomerase Is Associated with Increased Risk of Thrombosis in JAK2-Mutated Myeloproliferative Neoplasms. Clin Cancer Res. 2021 Oct 15;27(20):5708-5717. doi: 10.1158/1078-0432.CCR-21-1140. Epub 2021 Aug 16. PMID: 34400417; PMCID: PMC9170286.
Read more
Patell R, Bogue T, Koshy A, Bindal P, Merrill M, Aird WC, Bauer KA, Zwicker JI. Postdischarge thrombosis and hemorrhage in patients with COVID-19. Blood. 2020 Sep 10;136(11):1342-1346. doi: 10.1182/blood.2020007938. PMID: 32766883; PMCID: PMC7483433.
Zwicker JI, Schlechter BL, Stopa JD, Liebman HA, Aggarwal A, Puligandla M, Caughey T, Bauer KA, Kuemmerle N, Wong E, Wun T, McLaughlin M, Hidalgo M, Neuberg D, Furie B, Flaumenhaft R; CATIQ Investigators11. Targeting protein disulfide isomerase with the flavonoid isoquercetin to improve hypercoagulability in advanced cancer. JCI Insight. 2019 Feb 21;4(4):e125851. doi: 10.1172/jci.insight.125851. PMID: 30652973; PMCID: PMC6478409.
Visit PubMed for a full listing of Dr. Zwicker’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.
See all on PubMedPatient Reviews
Your trust is our main concern
We strive to keep reviews trustworthy, honest and fair. Learn more about our patient experience reviews.
Disclosures
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Jeffrey Zwicker discloses the following relationships and financial interests:
-
BioClinica
Professional Services and Activities -
CSL Behring
Professional Services and Activities -
International Society on Thrombosis and Haemostasis
Professional Services and Activities
-
Parexel International
Professional Services and Activities -
UptoDate
Intellectual Property Rights
If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2022 through disclosure submission in spring 2023). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].
